{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-26-000032","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2026-08-05T11:17:09+00:00","discovered_at":"2026-08-05T11:20:00.346446+00:00","generated_at":"2026-08-05T11:20:05.279172+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lifecore Q2 revenue $34.2M, down 6.2% YoY; net loss $6.2M vs $1.1M loss last year","bullets":["Revenue $34.2M, down 6.2% YoY; net loss $6.2M ($0.19 loss per share) vs $1.1M loss ($0.06) in prior year.","Adjusted EBITDA $8.6M, down from $9.1M; free cash flow $0.9M for six months ended June 30, 2026.","Reaffirmed 2026 guidance; targeting 12% revenue CAGR and >25% Adjusted EBITDA margin by end of 2029.","Added 13 new programs in past 12 months, including 8 late-stage; 6 new programs signed in Q2 2026.","Ended Q2 with $38.8M liquidity ($17.2M cash, $21.6M revolver availability)."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-26-000032","json":"https://secwatch.observer/filing/0001005286-26-000032.json","markdown":"https://secwatch.observer/filing/0001005286-26-000032.md","text":"https://secwatch.observer/filing/0001005286-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/0001005286-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528626000032/lfcr-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:20:05.279172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}